🔗

Mappings

MONDO

MONDO:0010246 developmental and epileptic encephalopathy, 9

MONDO:0010246 is the PCDH19 (DEE9 / EFMR) developmental and epileptic encephalopathy concept.

👪

Inheritance

1

X-linked inheritance with female-limited expression HP:0001417

PCDH19 is on the X chromosome, but expression is female-limited: heterozygous females are affected while hemizygous males are usually unaffected carriers, the opposite of the typical X-linked pattern. Most cases are de novo or inherited from an unaffected carrier father. Rare affected males carry a postzygotic (mosaic) PCDH19 variant.

X-linked inheritance

Show evidence (2 references)

PMID:18469813 SUPPORT Human Clinical

"EFMR spares transmitting males and affects only carrier females."

The founding study established the unusual female-limited, male-sparing inheritance pattern of the disorder.

PMID:19752159 SUPPORT Human Clinical

"can present de novo or in single generation families"

Documents the frequent de novo occurrence, consistent with the largely simplex presentation.

?

Discussions and Knowledge Gaps

3

Is cellular interference (pathological mis-sorting between protocadherin-19-positive and protocadherin-19-negative neurons in a mosaic brain) the complete explanation for PCDH19 clustering epilepsy, or do mosaicism-independent mechanisms such as altered neurogenesis and mitotic-spindle defects also contribute?

KNOWLEDGE GAP OPEN gap_pcdh19_cellular_interference_completeness

Attached to

pathophysiology#Cellular Interference and Impaired Homophilic Adhesion pathophysiology#Disrupted Neuronal Network Assembly

The cellular-interference model elegantly explains the female-limited, male-sparing inheritance: mosaic mice show abnormal cell sorting that is abolished by uniform deletion. But patient iPSC and organoid work points to additional, potentially mosaicism-independent phenotypes (precocious neurogenesis, mitotic-spindle and centrosome abnormalities), and some model data suggest phenotypes that do not require mosaicism. How much of the human disease is cellular interference versus a parallel cell-autonomous developmental defect is unresolved, and it shapes which mechanism a therapy should target.

Proposed experiments

Dissecting cellular interference from cell-autonomous defects

mosaic versus uniform comparison experiment

exp_pcdh19_interference_vs_cell_autonomous

Compare mosaic and uniform PCDH19-null human cortical organoids and mouse cortex for network excitability and developmental phenotypes, to partition which deficits require mosaicism (interference) and which persist in a uniform-genotype (cell-autonomous) context.

Readouts

Interference-dependent versus cell-autonomous phenotypes

pathophysiology#Disrupted Neuronal Network Assembly

multielectrode array recording immunostaining

Direction: POSITIVE

Controls

Wild-type uniform organoids

PCDH19-normal uniform organoids as the reference.

Decision criterion

A phenotype is interference-dependent if it appears in mosaic but not uniform-null tissue; it is cell-autonomous if it persists in uniform-null tissue.

Would support

pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

Show evidence (1 reference)

PMID:29301106 SUPPORT Model Organism

"Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."

Establishes cellular interference as a genuine mechanism; the open question is whether it is the whole story or whether cell-autonomous developmental defects also contribute.

Does PCDH19-associated allopregnanolone (neurosteroid) deficiency causally contribute to seizures via reduced GABA-A inhibition, and does it predict response to neurosteroid therapy such as ganaxolone?

EMERGING HYPOTHESIS OPEN gap_pcdh19_allopregnanolone_neurosteroid_hypothesis

Attached to

pathophysiology#Neuronal Network Hyperexcitability

Transcriptomic work in patient cells links PCDH19 dysfunction to reduced synthesis of allopregnanolone, a potent positive allosteric modulator of GABA-A receptors, suggesting a neurosteroid-deficiency arm that lowers inhibitory tone and could underlie the fever sensitivity. This motivated a ganaxolone trial, in which the seizure reduction versus placebo was larger but did not reach statistical significance. Whether allopregnanolone deficiency is causal (versus a bystander transcriptomic change) and whether a neurosteroid biomarker can select responders is the open question that determines the future of neurosteroid therapy in this disorder.

Proposed experiments

Allopregnanolone biomarker and neurosteroid-therapy response

biomarker-stratified treatment-response experiment

exp_pcdh19_neurosteroid_biomarker_response

In a prospective PCDH19 cohort, relate baseline serum allopregnanolone to seizure burden and to response to neurosteroid therapy, testing whether the biomarker identifies a neurosteroid-responsive subgroup.

Readouts

Seizure response by neurosteroid biomarker

pathophysiology#Neuronal Network Hyperexcitability

electroencephalography

Direction: NEGATIVE

Controls

Biomarker-normal patients

Patients without measurable allopregnanolone deficiency.

Decision criterion

The hypothesis is supported if lower baseline allopregnanolone predicts greater seizure reduction with neurosteroid therapy.

Would support

pathophysiology#Neuronal Network Hyperexcitability

Show evidence (2 references)

PMID:26123493 SUPPORT In Vitro

"deficiency of neurosteroid allopregnanolone, one of the most potent GABA"

Provides the mechanistic basis (allopregnanolone deficiency) for the neurosteroid hypothesis and for ganaxolone therapy.

PMID:36870093 SUPPORT Human Clinical

"The primary efficacy endpoint was the median percentage change in 28-day seizure frequency"

The trial tested the hypothesis clinically; the non-significant primary result leaves the causal and predictive value of the neurosteroid arm open.

How does the requirement for cellular mosaicism constrain therapeutic strategy in PCDH19 clustering epilepsy - in particular, does the mosaic-dependent mechanism make straightforward gene replacement counterproductive, and does the mosaic ratio (X-inactivation skew or somatic variant fraction) predict severity?

KNOWLEDGE GAP OPEN gap_pcdh19_mosaic_dependence_therapy_paradox

Attached to

pathophysiology#Mosaic Protocadherin-19 Expression pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

Because the pathogenic unit is the mismatched mosaic and not the null cell, the disorder poses an unusual therapeutic problem: uniformly restoring protocadherin-19 to all neurons would move a patient toward a uniform state (potentially beneficial), but partial or patchy correction could create new mosaic boundaries and additional interference. Meanwhile, affected mosaic males and the variable X-inactivation skew in females suggest the mosaic ratio may set severity. Whether mosaic fraction predicts outcome, and how to design a correction that does not recreate interference, are open questions with direct implications for gene- and cell-based therapy design.

Proposed experiments

Mosaic ratio, severity, and correction strategy

graded-mosaic correction experiment

exp_pcdh19_mosaic_ratio_and_correction

In graded-mosaic PCDH19 organoid and mouse systems, vary the fraction of protocadherin-19-null cells and measure network excitability, then test whether uniform correction versus partial correction improves or worsens the phenotype.

Readouts

Excitability versus mosaic fraction and correction

pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

multielectrode array recording

Direction: POSITIVE

Controls

Uniform wild-type and uniform null

Both uniform-genotype states as the non-mosaic references.

Decision criterion

A mosaic-ratio severity relationship is supported if intermediate mosaic fractions produce the greatest hyperexcitability; a correction is validated only if it reduces excitability without creating new interference.

Would support

pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

⚙

Pathophysiology

7

PCDH19 Loss-of-Function Variant

A loss-of-function variant in PCDH19 (missense, truncating, or deletion) abolishes or reduces functional protocadherin-19, a calcium-dependent cell-adhesion molecule of the delta-2 protocadherin family expressed in neurons. This node captures the single concept of the initiating genetic lesion.

PCDH19 hgnc:14270

Downstream

Mosaic Protocadherin-19 Expression In a heterozygous female (or mosaic male), the variant produces a mixture of protocadherin-19-positive and protocadherin-19-negative cells.

Show evidence (2 references)

PMID:18469813 SUPPORT Human Clinical

"Five mutations resulted in the introduction of a premature termination codon. Study of two of these demonstrated nonsense-mediated decay of PCDH19 mRNA."

Establishes the loss-of-function character of the initiating lesion: most of the founding mutations truncate the protein and are cleared by nonsense-mediated decay, so functional protocadherin-19 is absent from the mutant allele rather than merely altered.

PMID:18469813 SUPPORT Human Clinical

"The two missense mutations were predicted to affect adhesiveness of PCDH19 through impaired calcium binding."

Covers the missense arm of the same node and ties it to the calcium-dependent adhesion function that the downstream cellular-interference node depends on.

Mosaic Protocadherin-19 Expression

Because PCDH19 is subject to random X-chromosome inactivation, a heterozygous female is a mosaic of neurons expressing normal protocadherin-19 and neurons lacking it. A hemizygous male instead has a uniform, all-negative population. This node captures the single concept of the mosaic cell-population state that is necessary for disease.

Neuron CL:0000540

Downstream

Cellular Interference and Impaired Homophilic Adhesion The coexistence of positive and negative neuron populations sets up pathological cellular interference.

Show evidence (2 references)

PMID:29301106 SUPPORT Model Organism

"mosaic expression of Pcdh19 in heterozygous female mice leads to striking sorting between cells expressing wild-type (WT) PCDH19 and null PCDH19 in the developing cortex, correlating with altered network activity."

Demonstrates the mosaic cell-population state this node models, and shows it has a physical consequence in the developing cortex: positive and negative neurons segregate from one another, with altered network activity.

PMID:32366910 SUPPORT Human Clinical

"There were no phenotypic differences between heterozygous females and mosaic males."

Strong human support for mosaicism (not sex) being the operative variable: mosaic males, who share the mosaic cell population but not the female karyotype, are phenotypically indistinguishable from heterozygous females.

Cellular Interference and Impaired Homophilic Adhesion

Protocadherin-19 mediates calcium-dependent homophilic cell-cell adhesion. In a mosaic brain, protocadherin-19-positive and protocadherin-19-negative neurons cannot engage in normal homophilic interactions at their shared boundaries, so the mismatch itself (cellular interference), rather than simple loss of the protein, disrupts neuronal communication. This explains why uniform loss in hemizygous males is tolerated. This node captures the single concept of the cellular-interference mechanism.

Neuron CL:0000540

Homophilic cell-cell adhesion GO:0007156 ↕ DYSREGULATED

Downstream

Disrupted Neuronal Network Assembly Impaired adhesion between mismatched neuron populations disrupts the assembly and wiring of neuronal networks.

Show evidence (2 references)

PMID:29301106 SUPPORT Model Organism

"protocadherin 19 (PCDH19) mutations cause epilepsy in heterozygous females but spare hemizygous males."

States the paradoxical inheritance the cellular-interference model must explain.

PMID:29301106 SUPPORT Model Organism

"Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."

The pivotal result: removing the mosaic (uniform deletion) abolishes the abnormal cell sorting and normalizes activity, demonstrating that the mismatched mosaic - cellular interference - not simple loss of the protein, is pathogenic.

Disrupted Neuronal Network Assembly

Faulty protocadherin-19-dependent interactions perturb neuronal migration, sorting, and synaptic connectivity, yielding abnormally assembled cortical and limbic circuits. This node captures the single concept of the circuit-assembly defect.

Neuron CL:0000540

Downstream

Neuronal Network Hyperexcitability Abnormally assembled circuits become hyperexcitable, particularly under the provocation of fever.

Cognitive and Behavioral Impairment The same circuit-assembly defect underlies the cognitive and behavioral features.

Show evidence (2 references)

PMID:29301106 SUPPORT Model Organism

"Our results highlight the role of PCDH19 in determining cell adhesion affinities during cortical development and the way segregation of WT and null PCDH19 cells is associated with the unique X-linked inheritance of PCDH19 epilepsy."

Places the defect at the level of cortical developmental assembly, which is what this node asserts, rather than at ongoing synaptic function.

PMID:29301106 SUPPORT Human Clinical

"Furthermore, we identify variable cortical malformations in PCDH19 epilepsy patients."

Human structural correlate of the circuit-assembly defect. Rated PARTIAL because the malformations are described as variable, so they are not a constant feature and cannot carry the node on their own.

Neuronal Network Hyperexcitability

The disrupted networks are hyperexcitable and prone to hypersynchronous discharges, with a characteristic sensitivity to fever. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Fever-Sensitive Clustering Seizures Hyperexcitable networks generate the characteristic fever-sensitive seizure clusters.

Show evidence (1 reference)

PMID:29301106 SUPPORT Model Organism

"Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."

The rescue experiment shows network activity is abnormal in the mosaic state and normalizes when the mosaic is removed, which is the closest direct measurement of this node available. Rated PARTIAL because "altered network activity" in mouse cortex is not the same claim as the hypersynchronous, fever-sensitive hyperexcitability this node asserts in humans.

Fever-Sensitive Clustering Seizures

The clinical hallmark is seizures, often triggered or worsened by fever, that occur in tight clusters (many seizures over one or a few days separated by longer seizure-free intervals). Seizure types include focal, tonic-clonic, and absence. This node captures the single concept of the clustering-seizure endpoint and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Clustering Seizures Seizures occur in tight clusters over one or a few days separated by longer seizure-free intervals - the defining feature that names the disorder.

Focal-Onset Seizures The clusters are built predominantly from focal-onset seizures with prominent affective (fearful) semiology.

Fever-Sensitive Seizures The same endpoint is characteristically triggered or exacerbated by fever, especially at onset.

Bilateral Tonic-Clonic Seizures Bilateral tonic-clonic seizures are one of the seizure types making up the clusters.

Absence Seizures Absence (generalized non-motor) seizures occur within the seizure repertoire of some individuals.

Myoclonic Seizures Myoclonic seizures occur within the seizure repertoire of some individuals.

Atonic Seizures Atonic seizures occur within the seizure repertoire of some individuals.

Cognitive and Behavioral Impairment

Many affected individuals have intellectual disability of variable severity and behavioral features including autistic traits, hyperactivity, and aggression. This node captures the single concept of the cognitive/behavioral outcome.

Neuron CL:0000540

Downstream

Intellectual Disability The cognitive arm of the outcome is intellectual disability of variable severity.

Autistic Behavior Autistic features are a frequent component of the behavioral outcome.

Aggressive Behavior Behavioral disturbance including aggression is a frequent component of the same outcome.

Show evidence (2 references)

PMID:32366910 SUPPORT Human Clinical

"Executive dysfunction and autism spectrum disorder (ASD) occurred in approximately 60% of individuals."

Quantifies the cognitive and behavioral outcome in a 112-individual standardized-assessment cohort, supporting this node as a major arm of the disorder rather than an occasional accompaniment.

PMID:32366910 SUPPORT Human Clinical

"Earlier seizure onset age and increased number of seizures within a cluster were associated with more severe ASD symptoms (p = 0.001)"

Couples seizure burden to the severity of the behavioral outcome, the quantitative signal behind treating this node as downstream of the same circuit defect that drives the seizures.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Nervous System 7

Focal-Onset Seizures HP:0007359

Show evidence (1 reference)

PMID:32366910 SUPPORT Human Clinical

"focal seizure clusters with affective semiology"

Documents focal seizure clusters with affective semiology as a hallmark feature.

Fever-Sensitive Seizures Febrile seizure (within the age range of 3 months to 6 years) HP:0002373

Show evidence (1 reference)

PMID:39017914 SUPPORT Human Clinical

"The initial seizures usually develop in association with fever, begin on average at 15 months of age, and often occur in clusters."

States the fever association directly, together with the infantile onset and clustering this entry records alongside it.

Bilateral Tonic-Clonic Seizures HP:0002069

Absence Seizures Generalized non-motor (absence) seizure HP:0002121

Intellectual Disability HP:0001249

Show evidence (2 references)

PMID:30451291 SUPPORT Human Clinical

"Thirty-six patients (59.0%) had ID and behavioral disturbances."

Multicenter cohort of 61 patients putting intellectual disability with behavioral disturbance at 59%, supporting "common" in this description.

PMID:30451291 SUPPORT Human Clinical

"An earlier age at epilepsy onset emerged as the only predictive factor for ID (P = 0.047) and ASD (P = 0.014)."

Independently reproduces the onset-age/severity coupling reported by PMID:32366910 in a separate cohort, and is the basis for describing the cognitive outcome as variable in severity rather than uniform.

Autistic Behavior HP:0000729

Show evidence (2 references)

PMID:32366910 SUPPORT Human Clinical

"Executive dysfunction and autism spectrum disorder (ASD) occurred in approximately 60% of individuals."

Standardized assessment (Social Responsiveness Scale) in 112 individuals putting autism spectrum disorder at roughly 60%, well beyond "frequently associated".

PMID:32366910 SUPPORT Human Clinical

"The ASD profile included features of attention-deficit hyperactivity disorder."

Characterizes the autism profile, and is the source for the hyperactivity component named in this entry's disease description.

Aggressive Behavior HP:0000718

Other 3

Clustering Seizures Seizure cluster HP:0033349

Onset: INFANTILE

Show evidence (1 reference)

PMID:32366910 SUPPORT Human Clinical

"Seizures occurred in clusters in 94% of individuals"

Documents the near-universal seizure clustering, with typical seizure onset around 8 months of age.

Myoclonic Seizures HP:0032794

Atonic Seizures HP:0010819

🧬

Genetic Associations

1

PCDH19

Gene: PCDH19 hgnc:14270 relationship_type: CAUSATIVE

Show evidence (3 references)

PMID:18469813 SUPPORT Human Clinical

"Aided by systematic resequencing of 737 X chromosome genes, we identified different protocadherin 19 (PCDH19) gene mutations in seven families with EFMR."

The gene-discovery study establishing PCDH19 as causative, across seven independent EFMR families.

PMID:18469813 SUPPORT Human Clinical

"PCDH19 is expressed in developing brains of human and mouse and is the first member of the cadherin superfamily to be directly implicated in epilepsy or mental retardation."

Supports the notes' framing of PCDH19 as a brain-expressed cell-adhesion molecule, the property the cellular-interference mechanism turns on.

PMID:32366910 SUPPORT Human Clinical

"Of the 112 individuals represented (15 males), there were 70 unique variants."

Documents the allelic heterogeneity this notes block describes: 70 distinct variants across 112 individuals, with no single recurrent lesion dominating.

💊

Medical Actions

2

Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Agent: clobazam CHEBI:31413

Seizures are treated with antiseizure medications; clobazam and bromide are among the agents reported to help the clustering seizures, though seizures can be drug-resistant.

Neurosteroid Therapy

Action: Pharmacotherapy NCIT:C15986

Because PCDH19 loss has been linked to reduced neurosteroid (allopregnanolone) synthesis and consequent GABA-A hypofunction, the neurosteroid GABA-A positive allosteric modulator ganaxolone has been investigated as a targeted therapy.

Show evidence (2 references)

PMID:26123493 SUPPORT In Vitro

"deficiency of neurosteroid allopregnanolone, one of the most potent GABA"

Links PCDH19 dysfunction to reduced allopregnanolone (a GABA-A positive modulator), the mechanistic rationale for neurosteroid therapy.

PMID:36870093 SUPPORT Human Clinical

"The primary efficacy endpoint was the median percentage change in 28-day seizure frequency"

The VIOLET phase 2 trial evaluated ganaxolone; the larger seizure reduction versus placebo did not reach statistical significance, so the neurosteroid approach remains promising but unproven (supports: PARTIAL).

🔬

Diagnosis

1

PCDH19 Molecular Genetic Testing

Diagnosis is confirmed by identifying a pathogenic PCDH19 variant on molecular genetic testing in a female with clustering fever-sensitive seizures; because affected males are somatic mosaics, mosaicism-aware deep sequencing is needed to detect low-level variants in males. PCDH19 is a high-yield gene in SCN1A-negative Dravet-like females.

Show evidence (1 reference)

PMID:19214208 SUPPORT Human Clinical

"PCDH19 is responsible for a Dravet-like syndrome, we sequenced its coding region in 73 additional SCN1A-negative patients."

Establishes PCDH19 sequencing as the diagnostic test in SCN1A-negative Dravet-like patients.

📊

Prevalence

1

Worldwide

Unknown Rare

No precise cases-per-100,000 figure is well established. PCDH19 clustering epilepsy is nonetheless described as one of the most common monogenic epilepsies and, after SCN1A, a leading epilepsy gene; PCDH19 variants are found in a substantial fraction of SCN1A-negative Dravet-like females.

Show evidence (1 reference)

PMID:19214208 SUPPORT Human Clinical

"PCDH19 plays a major role in epileptic encephalopathies, with a clinical spectrum overlapping that of DS."

Supports the qualitative rarity/importance framing (a major epilepsy gene with a Dravet-overlapping spectrum); no normalized rate is asserted.

{ }

Source YAML

click to show

name: PCDH19 Clustering Epilepsy
creation_date: "2026-07-17T00:00:00Z"
category: Mendelian
description: >-
  PCDH19 clustering epilepsy (PCDH19-CE; historically epilepsy and mental
  retardation limited to females, EFMR; DEE9) is an X-linked developmental and
  epileptic encephalopathy with a distinctive inheritance pattern: heterozygous
  females are affected whereas hemizygous males are typically unaffected
  carriers. It presents in infancy or early childhood with fever-sensitive
  seizures that characteristically occur in clusters, and is variably associated
  with intellectual disability and behavioral features (autistic traits,
  hyperactivity, aggression). The paradoxical female-limited expression is
  explained by cellular interference: random X-chromosome inactivation in
  heterozygous females produces a mosaic of protocadherin-19-positive and
  protocadherin-19-negative neurons that cannot interact normally, whereas
  hemizygous males have a uniform (all-negative) neuronal population and are
  spared; rare mosaic males (somatic PCDH19 variant) are affected, supporting
  the model.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- PCDH19-related epilepsy
- Epilepsy, female-restricted, with mental retardation
- EFMR
- Developmental and epileptic encephalopathy 9
- DEE9
- Juberg-Hellman syndrome
disease_term:
  preferred_term: PCDH19 clustering epilepsy
  term:
    id: MONDO:0010246
    label: developmental and epileptic encephalopathy, 9
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010246
      label: developmental and epileptic encephalopathy, 9
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0010246 is the PCDH19 (DEE9 / EFMR) developmental and epileptic
      encephalopathy concept.
inheritance:
- name: X-linked inheritance with female-limited expression
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    PCDH19 is on the X chromosome, but expression is female-limited: heterozygous
    females are affected while hemizygous males are usually unaffected carriers,
    the opposite of the typical X-linked pattern. Most cases are de novo or
    inherited from an unaffected carrier father. Rare affected males carry a
    postzygotic (mosaic) PCDH19 variant.
  evidence:
  - reference: PMID:18469813
    reference_title: "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EFMR spares transmitting males and affects only carrier females."
    explanation: >-
      The founding study established the unusual female-limited, male-sparing
      inheritance pattern of the disorder.
  - reference: PMID:19752159
    reference_title: "Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "can present de novo or in single generation families"
    explanation: >-
      Documents the frequent de novo occurrence, consistent with the largely
      simplex presentation.
pathophysiology:
- name: PCDH19 Loss-of-Function Variant
  description: >-
    A loss-of-function variant in PCDH19 (missense, truncating, or deletion)
    abolishes or reduces functional protocadherin-19, a calcium-dependent
    cell-adhesion molecule of the delta-2 protocadherin family expressed in
    neurons. This node captures the single concept of the initiating genetic
    lesion.
  role: trigger
  gene:
    preferred_term: PCDH19
    term:
      id: hgnc:14270
      label: PCDH19
  evidence:
  - reference: PMID:18469813
    reference_title: "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five mutations resulted in the introduction of a premature termination codon. Study of two of these demonstrated nonsense-mediated decay of PCDH19 mRNA."
    explanation: >-
      Establishes the loss-of-function character of the initiating lesion: most
      of the founding mutations truncate the protein and are cleared by
      nonsense-mediated decay, so functional protocadherin-19 is absent from the
      mutant allele rather than merely altered.
  - reference: PMID:18469813
    reference_title: "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The two missense mutations were predicted to affect adhesiveness of PCDH19 through impaired calcium binding."
    explanation: >-
      Covers the missense arm of the same node and ties it to the
      calcium-dependent adhesion function that the downstream
      cellular-interference node depends on.
  downstream:
  - target: Mosaic Protocadherin-19 Expression
    causal_link_type: DIRECT
    description: >-
      In a heterozygous female (or mosaic male), the variant produces a mixture
      of protocadherin-19-positive and protocadherin-19-negative cells.
- name: Mosaic Protocadherin-19 Expression
  description: >-
    Because PCDH19 is subject to random X-chromosome inactivation, a heterozygous
    female is a mosaic of neurons expressing normal protocadherin-19 and neurons
    lacking it. A hemizygous male instead has a uniform, all-negative population.
    This node captures the single concept of the mosaic cell-population state
    that is necessary for disease.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mosaic expression of Pcdh19 in heterozygous female mice leads to striking sorting between cells expressing wild-type (WT) PCDH19 and null PCDH19 in the developing cortex, correlating with altered network activity."
    explanation: >-
      Demonstrates the mosaic cell-population state this node models, and shows
      it has a physical consequence in the developing cortex: positive and
      negative neurons segregate from one another, with altered network
      activity.
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were no phenotypic differences between heterozygous females and mosaic males."
    explanation: >-
      Strong human support for mosaicism (not sex) being the operative variable:
      mosaic males, who share the mosaic cell population but not the female
      karyotype, are phenotypically indistinguishable from heterozygous females.
  downstream:
  - target: Cellular Interference and Impaired Homophilic Adhesion
    causal_link_type: DIRECT
    description: >-
      The coexistence of positive and negative neuron populations sets up
      pathological cellular interference.
- name: Cellular Interference and Impaired Homophilic Adhesion
  description: >-
    Protocadherin-19 mediates calcium-dependent homophilic cell-cell adhesion.
    In a mosaic brain, protocadherin-19-positive and protocadherin-19-negative
    neurons cannot engage in normal homophilic interactions at their shared
    boundaries, so the mismatch itself (cellular interference), rather than
    simple loss of the protein, disrupts neuronal communication. This explains
    why uniform loss in hemizygous males is tolerated. This node captures the
    single concept of the cellular-interference mechanism.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Homophilic cell-cell adhesion
    term:
      id: GO:0007156
      label: homophilic cell-cell adhesion
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "protocadherin 19 (PCDH19) mutations cause epilepsy in heterozygous females but spare hemizygous males."
    explanation: >-
      States the paradoxical inheritance the cellular-interference model must
      explain.
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."
    explanation: >-
      The pivotal result: removing the mosaic (uniform deletion) abolishes the
      abnormal cell sorting and normalizes activity, demonstrating that the
      mismatched mosaic - cellular interference - not simple loss of the
      protein, is pathogenic.
  downstream:
  - target: Disrupted Neuronal Network Assembly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Impaired adhesion between mismatched neuron populations disrupts the
      assembly and wiring of neuronal networks.
- name: Disrupted Neuronal Network Assembly
  description: >-
    Faulty protocadherin-19-dependent interactions perturb neuronal migration,
    sorting, and synaptic connectivity, yielding abnormally assembled cortical
    and limbic circuits. This node captures the single concept of the
    circuit-assembly defect.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results highlight the role of PCDH19 in determining cell adhesion affinities during cortical development and the way segregation of WT and null PCDH19 cells is associated with the unique X-linked inheritance of PCDH19 epilepsy."
    explanation: >-
      Places the defect at the level of cortical developmental assembly, which
      is what this node asserts, rather than at ongoing synaptic function.
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, we identify variable cortical malformations in PCDH19 epilepsy patients."
    explanation: >-
      Human structural correlate of the circuit-assembly defect. Rated PARTIAL
      because the malformations are described as variable, so they are not a
      constant feature and cannot carry the node on their own.
  downstream:
  - target: Neuronal Network Hyperexcitability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Abnormally assembled circuits become hyperexcitable, particularly under
      the provocation of fever.
  - target: Cognitive and Behavioral Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The same circuit-assembly defect underlies the cognitive and behavioral
      features.
- name: Neuronal Network Hyperexcitability
  description: >-
    The disrupted networks are hyperexcitable and prone to hypersynchronous
    discharges, with a characteristic sensitivity to fever. This node captures
    the single concept of network hyperexcitability and conforms to the shared
    epilepsy final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."
    explanation: >-
      The rescue experiment shows network activity is abnormal in the mosaic
      state and normalizes when the mosaic is removed, which is the closest
      direct measurement of this node available. Rated PARTIAL because "altered
      network activity" in mouse cortex is not the same claim as the
      hypersynchronous, fever-sensitive hyperexcitability this node asserts in
      humans.
  downstream:
  - target: Fever-Sensitive Clustering Seizures
    causal_link_type: DIRECT
    description: >-
      Hyperexcitable networks generate the characteristic fever-sensitive
      seizure clusters.
- name: Fever-Sensitive Clustering Seizures
  description: >-
    The clinical hallmark is seizures, often triggered or worsened by fever,
    that occur in tight clusters (many seizures over one or a few days separated
    by longer seizure-free intervals). Seizure types include focal, tonic-clonic,
    and absence. This node captures the single concept of the clustering-seizure
    endpoint and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Clustering Seizures
    causal_link_type: DIRECT
    description: >-
      Seizures occur in tight clusters over one or a few days separated by
      longer seizure-free intervals - the defining feature that names the
      disorder.
    evidence:
    - reference: PMID:32366910
      reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seizures occurred in clusters in 94% of individuals"
      explanation: >-
        PARTIAL: the cohort establishes that clustering is near-universal, which
        is this edge's target, but reports the clinical observation rather than
        the mechanism-to-manifestation step the edge encodes.
  - target: Focal-Onset Seizures
    causal_link_type: DIRECT
    description: >-
      The clusters are built predominantly from focal-onset seizures with
      prominent affective (fearful) semiology.
    evidence:
    - reference: PMID:32366910
      reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "focal seizure clusters with affective semiology"
      explanation: >-
        INDIRECT: documents focal seizure clusters with affective semiology as the
        hallmark presentation, establishing the edge's target without asserting
        the causal step.
  - target: Fever-Sensitive Seizures
    causal_link_type: DIRECT
    description: >-
      The same endpoint is characteristically triggered or exacerbated by fever,
      especially at onset.
  - target: Bilateral Tonic-Clonic Seizures
    causal_link_type: DIRECT
    description: >-
      Bilateral tonic-clonic seizures are one of the seizure types making up the
      clusters.
  - target: Absence Seizures
    causal_link_type: DIRECT
    description: >-
      Absence (generalized non-motor) seizures occur within the seizure
      repertoire of some individuals.
  - target: Myoclonic Seizures
    causal_link_type: DIRECT
    description: >-
      Myoclonic seizures occur within the seizure repertoire of some
      individuals.
  - target: Atonic Seizures
    causal_link_type: DIRECT
    description: >-
      Atonic seizures occur within the seizure repertoire of some individuals.
- name: Cognitive and Behavioral Impairment
  description: >-
    Many affected individuals have intellectual disability of variable severity
    and behavioral features including autistic traits, hyperactivity, and
    aggression. This node captures the single concept of the
    cognitive/behavioral outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Executive dysfunction and autism spectrum disorder (ASD) occurred in approximately 60% of individuals."
    explanation: >-
      Quantifies the cognitive and behavioral outcome in a 112-individual
      standardized-assessment cohort, supporting this node as a major arm of the
      disorder rather than an occasional accompaniment.
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Earlier seizure onset age and increased number of seizures within a cluster were associated with more severe ASD symptoms (p = 0.001)"
    explanation: >-
      Couples seizure burden to the severity of the behavioral outcome, the
      quantitative signal behind treating this node as downstream of the same
      circuit defect that drives the seizures.
  downstream:
  - target: Intellectual Disability
    causal_link_type: DIRECT
    description: >-
      The cognitive arm of the outcome is intellectual disability of variable
      severity.
  - target: Autistic Behavior
    causal_link_type: DIRECT
    description: >-
      Autistic features are a frequent component of the behavioral outcome.
  - target: Aggressive Behavior
    causal_link_type: DIRECT
    description: >-
      Behavioral disturbance including aggression is a frequent component of the
      same outcome.
phenotypes:
- name: Clustering Seizures
  description: >-
    Seizures characteristically occur in clusters over one or a few days,
    separated by longer seizure-free intervals - the defining feature that gives
    the disorder its name.
  phenotype_term:
    preferred_term: Seizure cluster
    term:
      id: HP:0033349
      label: Seizure cluster
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures occurred in clusters in 94% of individuals"
    explanation: >-
      Documents the near-universal seizure clustering, with typical seizure
      onset around 8 months of age.
- name: Focal-Onset Seizures
  description: >-
    The characteristic seizures of PCDH19 clustering epilepsy are focal-onset
    with prominent affective (fearful) semiology, frequently fever-triggered.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "focal seizure clusters with affective semiology"
    explanation: >-
      Documents focal seizure clusters with affective semiology as a hallmark
      feature.
- name: Fever-Sensitive Seizures
  description: >-
    Seizures are frequently triggered or exacerbated by fever, especially at
    onset.
  phenotype_term:
    preferred_term: Febrile seizure
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
  evidence:
  - reference: PMID:39017914
    reference_title: "Multicenter retrospective study of patients with PCDH19-related epilepsy: The first Hungarian cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The initial seizures usually develop in association with fever, begin on average at 15 months of age, and often occur in clusters."
    explanation: >-
      States the fever association directly, together with the infantile onset
      and clustering this entry records alongside it.
- name: Bilateral Tonic-Clonic Seizures
  description: Generalized (bilateral) tonic-clonic seizures occur.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
- name: Absence Seizures
  description: Absence (generalized non-motor) seizures occur in some individuals.
  phenotype_term:
    preferred_term: Absence seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
- name: Intellectual Disability
  description: >-
    Intellectual disability of variable severity is common.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:30451291
    reference_title: "Defining the electroclinical phenotype and outcome of PCDH19-related epilepsy: A multicenter study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-six patients (59.0%) had ID and behavioral disturbances."
    explanation: >-
      Multicenter cohort of 61 patients putting intellectual disability with
      behavioral disturbance at 59%, supporting "common" in this description.
  - reference: PMID:30451291
    reference_title: "Defining the electroclinical phenotype and outcome of PCDH19-related epilepsy: A multicenter study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An earlier age at epilepsy onset emerged as the only predictive factor for ID (P = 0.047) and ASD (P = 0.014)."
    explanation: >-
      Independently reproduces the onset-age/severity coupling reported by
      PMID:32366910 in a separate cohort, and is the basis for describing the
      cognitive outcome as variable in severity rather than uniform.
- name: Autistic Behavior
  description: Autistic features are frequently associated.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Executive dysfunction and autism spectrum disorder (ASD) occurred in approximately 60% of individuals."
    explanation: >-
      Standardized assessment (Social Responsiveness Scale) in 112 individuals
      putting autism spectrum disorder at roughly 60%, well beyond "frequently
      associated".
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ASD profile included features of attention-deficit hyperactivity disorder."
    explanation: >-
      Characterizes the autism profile, and is the source for the hyperactivity
      component named in this entry's disease description.
- name: Aggressive Behavior
  description: Behavioral disturbance including aggression is frequent.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
- name: Myoclonic Seizures
  description: Myoclonic seizures occur in some individuals.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
- name: Atonic Seizures
  description: Atonic seizures occur in some individuals.
  phenotype_term:
    preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
genetic:
- name: PCDH19
  gene_term:
    preferred_term: PCDH19
    term:
      id: hgnc:14270
      label: PCDH19
  relationship_type: CAUSATIVE
  notes: >-
    PCDH19 (Xq22.1) encodes protocadherin-19, a calcium-dependent homophilic
    cell-adhesion molecule. Disease requires a mosaic of positive and negative
    neurons: heterozygous females (via random X-inactivation) and rare mosaic
    males are affected, whereas hemizygous (uniformly negative) males are usually
    unaffected carriers. Variants include missense, truncating, and whole-gene
    deletions.
  evidence:
  - reference: PMID:18469813
    reference_title: "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aided by systematic resequencing of 737 X chromosome genes, we identified different protocadherin 19 (PCDH19) gene mutations in seven families with EFMR."
    explanation: >-
      The gene-discovery study establishing PCDH19 as causative, across seven
      independent EFMR families.
  - reference: PMID:18469813
    reference_title: "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PCDH19 is expressed in developing brains of human and mouse and is the first member of the cadherin superfamily to be directly implicated in epilepsy or mental retardation."
    explanation: >-
      Supports the notes' framing of PCDH19 as a brain-expressed cell-adhesion
      molecule, the property the cellular-interference mechanism turns on.
  - reference: PMID:32366910
    reference_title: "A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 112 individuals represented (15 males), there were 70 unique variants."
    explanation: >-
      Documents the allelic heterogeneity this notes block describes: 70 distinct
      variants across 112 individuals, with no single recurrent lesion dominating.
diagnosis:
- name: PCDH19 Molecular Genetic Testing
  description: >-
    Diagnosis is confirmed by identifying a pathogenic PCDH19 variant on
    molecular genetic testing in a female with clustering fever-sensitive
    seizures; because affected males are somatic mosaics, mosaicism-aware deep
    sequencing is needed to detect low-level variants in males. PCDH19 is a
    high-yield gene in SCN1A-negative Dravet-like females.
  evidence:
  - reference: PMID:19214208
    reference_title: "Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PCDH19 is responsible for a Dravet-like syndrome, we sequenced its coding region in 73 additional SCN1A-negative patients."
    explanation: >-
      Establishes PCDH19 sequencing as the diagnostic test in SCN1A-negative
      Dravet-like patients.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: RARE
  notes: >-
    No precise cases-per-100,000 figure is well established. PCDH19 clustering
    epilepsy is nonetheless described as one of the most common monogenic
    epilepsies and, after SCN1A, a leading epilepsy gene; PCDH19 variants are
    found in a substantial fraction of SCN1A-negative Dravet-like females.
  evidence:
  - reference: PMID:19214208
    reference_title: "Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PCDH19 plays a major role in epileptic encephalopathies, with a clinical spectrum overlapping that of DS."
    explanation: >-
      Supports the qualitative rarity/importance framing (a major epilepsy gene
      with a Dravet-overlapping spectrum); no normalized rate is asserted.
treatments:
- name: Antiseizure Medication
  description: >-
    Seizures are treated with antiseizure medications; clobazam and bromide are
    among the agents reported to help the clustering seizures, though seizures
    can be drug-resistant.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
- name: Neurosteroid Therapy
  description: >-
    Because PCDH19 loss has been linked to reduced neurosteroid (allopregnanolone)
    synthesis and consequent GABA-A hypofunction, the neurosteroid GABA-A
    positive allosteric modulator ganaxolone has been investigated as a targeted
    therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:26123493
    reference_title: "Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "deficiency of neurosteroid allopregnanolone, one of the most potent GABA"
    explanation: >-
      Links PCDH19 dysfunction to reduced allopregnanolone (a GABA-A positive
      modulator), the mechanistic rationale for neurosteroid therapy.
  - reference: PMID:36870093
    reference_title: "Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary efficacy endpoint was the median percentage change in 28-day seizure frequency"
    explanation: >-
      The VIOLET phase 2 trial evaluated ganaxolone; the larger seizure
      reduction versus placebo did not reach statistical significance, so the
      neurosteroid approach remains promising but unproven (supports: PARTIAL).
datasets: []
discussions:
- discussion_id: gap_pcdh19_cellular_interference_completeness
  prompt: >-
    Is cellular interference (pathological mis-sorting between
    protocadherin-19-positive and protocadherin-19-negative neurons in a mosaic
    brain) the complete explanation for PCDH19 clustering epilepsy, or do
    mosaicism-independent mechanisms such as altered neurogenesis and
    mitotic-spindle defects also contribute?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cellular Interference and Impaired Homophilic Adhesion
  - pathophysiology#Disrupted Neuronal Network Assembly
  rationale: >-
    The cellular-interference model elegantly explains the female-limited,
    male-sparing inheritance: mosaic mice show abnormal cell sorting that is
    abolished by uniform deletion. But patient iPSC and organoid work points to
    additional, potentially mosaicism-independent phenotypes (precocious
    neurogenesis, mitotic-spindle and centrosome abnormalities), and some model
    data suggest phenotypes that do not require mosaicism. How much of the human
    disease is cellular interference versus a parallel cell-autonomous
    developmental defect is unresolved, and it shapes which mechanism a therapy
    should target.
  evidence:
  - reference: PMID:29301106
    reference_title: "Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Complete deletion of PCDH19 in heterozygous mice abolishes abnormal cell sorting and restores normal network activity."
    explanation: >-
      Establishes cellular interference as a genuine mechanism; the open question
      is whether it is the whole story or whether cell-autonomous developmental
      defects also contribute.
  proposed_experiments:
  - experiment_id: exp_pcdh19_interference_vs_cell_autonomous
    name: Dissecting cellular interference from cell-autonomous defects
    description: >-
      Compare mosaic and uniform PCDH19-null human cortical organoids and mouse
      cortex for network excitability and developmental phenotypes, to partition
      which deficits require mosaicism (interference) and which persist in a
      uniform-genotype (cell-autonomous) context.
    experiment_type:
      preferred_term: mosaic versus uniform comparison experiment
    readouts:
    - name: Interference-dependent versus cell-autonomous phenotypes
      target: pathophysiology#Disrupted Neuronal Network Assembly
      assays:
      - preferred_term: multielectrode array recording
      - preferred_term: immunostaining
      direction: POSITIVE
    controls:
    - name: Wild-type uniform organoids
      description: PCDH19-normal uniform organoids as the reference.
    decision_criterion: >-
      A phenotype is interference-dependent if it appears in mosaic but not
      uniform-null tissue; it is cell-autonomous if it persists in uniform-null
      tissue.
    would_support:
    - pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

- discussion_id: gap_pcdh19_allopregnanolone_neurosteroid_hypothesis
  prompt: >-
    Does PCDH19-associated allopregnanolone (neurosteroid) deficiency causally
    contribute to seizures via reduced GABA-A inhibition, and does it predict
    response to neurosteroid therapy such as ganaxolone?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  attaches_to:
  - pathophysiology#Neuronal Network Hyperexcitability
  rationale: >-
    Transcriptomic work in patient cells links PCDH19 dysfunction to reduced
    synthesis of allopregnanolone, a potent positive allosteric modulator of
    GABA-A receptors, suggesting a neurosteroid-deficiency arm that lowers
    inhibitory tone and could underlie the fever sensitivity. This motivated a
    ganaxolone trial, in which the seizure reduction versus placebo was larger
    but did not reach statistical significance. Whether allopregnanolone
    deficiency is causal (versus a bystander transcriptomic change) and whether a
    neurosteroid biomarker can select responders is the open question that
    determines the future of neurosteroid therapy in this disorder.
  evidence:
  - reference: PMID:26123493
    reference_title: "Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "deficiency of neurosteroid allopregnanolone, one of the most potent GABA"
    explanation: >-
      Provides the mechanistic basis (allopregnanolone deficiency) for the
      neurosteroid hypothesis and for ganaxolone therapy.
  - reference: PMID:36870093
    reference_title: "Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary efficacy endpoint was the median percentage change in 28-day seizure frequency"
    explanation: >-
      The trial tested the hypothesis clinically; the non-significant primary
      result leaves the causal and predictive value of the neurosteroid arm open.
  proposed_experiments:
  - experiment_id: exp_pcdh19_neurosteroid_biomarker_response
    name: Allopregnanolone biomarker and neurosteroid-therapy response
    description: >-
      In a prospective PCDH19 cohort, relate baseline serum allopregnanolone to
      seizure burden and to response to neurosteroid therapy, testing whether the
      biomarker identifies a neurosteroid-responsive subgroup.
    experiment_type:
      preferred_term: biomarker-stratified treatment-response experiment
    readouts:
    - name: Seizure response by neurosteroid biomarker
      target: pathophysiology#Neuronal Network Hyperexcitability
      assays:
      - preferred_term: electroencephalography
      direction: NEGATIVE
    controls:
    - name: Biomarker-normal patients
      description: Patients without measurable allopregnanolone deficiency.
    decision_criterion: >-
      The hypothesis is supported if lower baseline allopregnanolone predicts
      greater seizure reduction with neurosteroid therapy.
    would_support:
    - pathophysiology#Neuronal Network Hyperexcitability

- discussion_id: gap_pcdh19_mosaic_dependence_therapy_paradox
  prompt: >-
    How does the requirement for cellular mosaicism constrain therapeutic
    strategy in PCDH19 clustering epilepsy - in particular, does the
    mosaic-dependent mechanism make straightforward gene replacement
    counterproductive, and does the mosaic ratio (X-inactivation skew or somatic
    variant fraction) predict severity?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Mosaic Protocadherin-19 Expression
  - pathophysiology#Cellular Interference and Impaired Homophilic Adhesion
  rationale: >-
    Because the pathogenic unit is the mismatched mosaic and not the null cell,
    the disorder poses an unusual therapeutic problem: uniformly restoring
    protocadherin-19 to all neurons would move a patient toward a uniform state
    (potentially beneficial), but partial or patchy correction could create new
    mosaic boundaries and additional interference. Meanwhile, affected mosaic
    males and the variable X-inactivation skew in females suggest the mosaic
    ratio may set severity. Whether mosaic fraction predicts outcome, and how to
    design a correction that does not recreate interference, are open questions
    with direct implications for gene- and cell-based therapy design.
  proposed_experiments:
  - experiment_id: exp_pcdh19_mosaic_ratio_and_correction
    name: Mosaic ratio, severity, and correction strategy
    description: >-
      In graded-mosaic PCDH19 organoid and mouse systems, vary the fraction of
      protocadherin-19-null cells and measure network excitability, then test
      whether uniform correction versus partial correction improves or worsens
      the phenotype.
    experiment_type:
      preferred_term: graded-mosaic correction experiment
    readouts:
    - name: Excitability versus mosaic fraction and correction
      target: pathophysiology#Cellular Interference and Impaired Homophilic Adhesion
      assays:
      - preferred_term: multielectrode array recording
      direction: POSITIVE
    controls:
    - name: Uniform wild-type and uniform null
      description: Both uniform-genotype states as the non-mosaic references.
    decision_criterion: >-
      A mosaic-ratio severity relationship is supported if intermediate mosaic
      fractions produce the greatest hyperexcitability; a correction is validated
      only if it reduces excitability without creating new interference.
    would_support:
    - pathophysiology#Cellular Interference and Impaired Homophilic Adhesion

📚

References & Deep Research

Deep Research

1

Claude Code ▸

PCDH19 Clustering Epilepsy — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-4-8 22 citations 2026-07-17T23:35:18.380895

PCDH19 Clustering Epilepsy — Comprehensive Research Report

Prepared for dismech KB curation | Category: Mendelian (X-linked)

A quick word before we wade in, since this is going into a knowledge base: I've pulled PMIDs from the literature and from search, but per the project's own anti-hallucination SOP, treat every PMID and quote below as a lead to verify with just fetch-reference PMID:XXXX before it becomes an evidence snippet. I've flagged the handful where my confidence on the exact PMID digits is softer. The ontology IDs (MONDO/HGNC) I pulled straight from the local OAK adapters, so those are solid.

PCDH19 is one of biology's little contrarians. It sits on the X chromosome, and yet it breaks the classic X-linked rulebook completely backwards — the girls (heterozygous) get the disease, and the boys carrying the exact same broken copy (hemizygous) mostly walk away fine. The disease needs the mosaic. A brain that's uniformly broken is, paradoxically, a brain that works. That's the whole strange heart of this thing, and it drives basically every section below.

1. Disease Information

Overview. PCDH19 Clustering Epilepsy (PCDH19-CE) is an X-linked developmental and epileptic encephalopathy caused by loss-of-function variants in PCDH19 (protocadherin 19). Its signature is early-life seizures that come in tight clusters, are strongly fever-sensitive, and are frequently accompanied by intellectual disability, autism spectrum features, and other neuropsychiatric problems. It affects females and rare mosaic males, while "transmitting" hemizygous males are typically spared.

Key identifiers (verified against local MONDO/HGNC adapters):

Resource	ID
MONDO	MONDO:0010246 (developmental and epileptic encephalopathy, 9)
OMIM (phenotype)	#300088 (DEE9; formerly EIEE9 / EFMR)
OMIM (gene)	*300460 (PCDH19)
HGNC	hgnc:14270 (PCDH19) — note the lowercase-prefix convention this repo uses
Orphanet	ORPHA:101039
DOID	DOID:0060848
MeSH	C564715
UMLS	C1848137 · MedGen 338393 · GARD 0010806
Cytogenetic location	Xq22.1 (OMIM lists Xq22)

Synonyms / alternative names (from MONDO): DEE9; EIEE9; EFMR (Epilepsy and Mental Retardation Limited to Females); Epilepsy, Female-restricted, with Mental Retardation; PCDH19-related female-limited epilepsy (PCDH19-FE / FLE); PCDH19-related infantile epileptic encephalopathy; Juberg-Hellman syndrome; "Girls Clustering Epilepsy." The field has largely converged on "PCDH19 Clustering Epilepsy" because the older names got the sex-limitation and the ID emphasis slightly wrong (mosaic males exist; many patients have normal intellect).

Data provenance. Disease-level aggregated resources (OMIM, Orphanet, MONDO) plus cohort/case-series literature. Not EHR-derived at the individual level; the large phenotyping series (e.g. Kolc et al., Transl Psychiatry 2020, PMID:32366910) are patient-registry/cohort aggregations.

MONDO places it as a subclass of X-linked intellectual disability–epilepsy syndrome (MONDO:0016160), genetic developmental and epileptic encephalopathy (MONDO:0100062), and X-linked complex neurodevelopmental disorder (MONDO:0100148).

2. Etiology

Primary cause — genetic. Heterozygous (female) or mosaic (male) loss-of-function variants in PCDH19. This is a monogenic disorder; there is no established environmental cause. Fever/illness is a potent trigger/precipitant of seizure clusters, not a cause of the disease itself.

Genetic risk factors. - The causal event is the PCDH19 variant. There is no separate "susceptibility locus" architecture in the GWAS sense — this is Mendelian. - Sex is the dominant effect modifier: being female (constitutively mosaic via random X-inactivation) is effectively the prerequisite for the classic phenotype. Genetic males require somatic mosaicism to be affected. - X-inactivation skewing plausibly modulates the mutant:wild-type cell ratio and hence severity, though a clean genotype–XCI–severity correlation has not been firmly nailed down.

Environmental / trigger factors. Febrile illness is the archetypal precipitant of clusters; vaccination-associated fever and intercurrent infection are commonly reported cluster triggers. These modulate expression/timing, not disease occurrence.

Protective factors. None genetically established. The most striking "protective" observation is the counterintuitive one: uniform hemizygous expression of mutant PCDH19 in males is protective against the epilepsy (the mosaic, not the mutation per se, is pathogenic) — the cellular-interference logic in §6.

Gene–environment interaction. The central G×E axis is variant × febrile/inflammatory stress: the mutant mosaic brain has a lowered threshold such that fever/illness reliably pushes it into clustered seizures. There is emerging interest in a blood–brain-barrier / neuroinflammation contribution to that fever sensitivity (see §6).

3. Phenotypes

Frequencies below are anchored to the standardized phenotyping cohort (Kolc et al. 2020, PMID:32366910, n≈112) and corroborating series.

Seizures (core). - Seizure clusters — the defining feature: 94% (106/112) had clustered seizures. Clusters averaged ~4.6 days and ~15 seizures each (range 2–100). → HPO HP:0032807 Cluster of seizures (verify exact HP label); HP:0001250 Seizure. - Focal (focal-onset) seizures, often with a fearful/affective component ("fearful screaming") — highly characteristic. → HP:0007359 Focal-onset seizure. - Febrile / fever-sensitive seizures — clusters typically ignited by fever. → HP:0002373 Febrile seizure / HP:0011171 Generalized-onset seizure as applicable; consider temporality: RECURRENT. - Also tonic-clonic, tonic, absence, myoclonic, atonic seizures reported. → HP:0002069, HP:0032792, HP:0002121, HP:0002123, HP:0010819.

Neurodevelopmental / cognitive. - Intellectual disability — spectrum, and importantly ~56% have normal intellect in the standardized cohort; among the rest: mild 18%, moderate 8%, severe 12.5%, profound 2%. → HP:0001249 Intellectual disability (severity qualifier variable). - Autism spectrum disorder — ~62% met ASD criteria. → HP:0000717 Autism. - Executive dysfunction — ~63%. → HP:0002019-adjacent / behavioral abnormality terms. - ADHD / hyperactivity — frequently reported. → HP:0007018 Attention deficit hyperactivity disorder. - Obsessive-compulsive / psychiatric features — OCD ~21% of assessed; psychiatric risk (including psychotic/schizophrenia-spectrum disorders) rises in adulthood. → HP:0000722 Obsessive-compulsive behavior; HP:0100753 Schizophrenia. - Aggression, mood/behavioral disturbance common. → HP:0000718 Aggressive behavior.

Phenotype characteristics (summary). - Onset: infancy/early childhood; mean ~12 months, median ~10 months in females (range 1.5–60 mo); OMIM/Orphanet quote ~10 months average, range ~2 mo–3 yr. - Severity: variable — from normal-cognition/seizure-limited to severe DEE. - Course: episodic/clustered seizure pattern superimposed on a chronic disorder; many see seizure attenuation in later childhood/adolescence. - Genotype-independent severity driver: earlier onset + higher seizure burden → worse ID, ASD, executive dysfunction (Kolc 2020: association p=0.001 for ASD, p≈4.7×10⁻⁴ for executive dysfunction).

Quality-of-life impact. High: 75% scored "very high" on SDQ impact. Cluster unpredictability, fever-triggered emergencies, and neuropsychiatric comorbidity dominate family burden; adult psychiatric risk is a major long-horizon concern.

4. Genetic / Molecular Information

Causal gene. PCDH19 (protocadherin 19), Xq22.1, OMIM *300460, hgnc:14270. Encodes a δ2-protocadherin, a non-clustered member of the cadherin superfamily — a calcium-dependent cell–cell adhesion glycoprotein predominantly expressed in brain. Domain architecture: 6 extracellular cadherin (EC) repeats, a transmembrane domain, and a cytoplasmic tail with conserved motifs CM1/CM2 (per protocadherin structure review, PMID:34201522 — verify).

Pathogenic variants. - Variant types: the full loss-of-function spectrum — missense, nonsense, frameshift (small indels), splice-site, and whole/partial-gene deletions; a triplication mechanism has also been described (MDPI Genes 2024, PMC11506946). Missense variants cluster in the extracellular cadherin domains (EC1–EC6), consistent with disrupted homophilic adhesion. - >120 distinct variants reported; most are family-specific/private, with a handful of recurrent ones. - De novo rate: ~48–70% across cohorts (Kolc 2020: 48% de novo; epilepsiome/clinical reviews cite ~70%). - Classification: per ACMG/AMP, LoF is an established mechanism, so null variants are readily P/LP; missense VUS burden exists — check ClinVar/ClinGen. - Allele frequency: pathogenic variants are essentially absent from population controls (gnomAD) given severity/de-novo nature. - Somatic vs germline: germline in females; affected males are typically postzygotic somatic mosaics (variant allele fraction correlates loosely with phenotype severity — PMC9669318). - Functional consequence: loss of function / haploinsufficiency at the cellular level, but the pathogenic unit is the mosaic tissue, not the single null cell.

Modifier genes / downstream expression. PCDH19 dysfunction perturbs steroidogenic gene expression — notably genes in the allopregnanolone (neurosteroid) synthesis pathway (e.g. AKR1C1/2/3, CYP steroidogenic enzymes), yielding an "allopregnanolone deficiency" signature in patients (Tan et al. 2015 — verify PMID). This is both a candidate modifier axis and a therapeutic hook (§12).

Epigenetic. No established disease-defining methylation signature (episignature) as of current literature; X-inactivation is the dominant epigenetic determinant because it sets the mosaic ratio. Worth flagging as a knowledge gap.

Chromosomal abnormalities. Large PCDH19 deletions and the reported triplication are detectable by CMA; otherwise this is a single-gene disorder, not an aneuploidy syndrome.

Suggested annotations: gene hgnc:14270; GO cellular component GO:0005911 cell-cell junction / GO:0005912 adherens junction; molecular function GO:0005509 calcium ion binding, GO:0098631 cell adhesion mediator activity.

5. Environmental Information

Environmental factors: no toxin/pollutant/radiation etiology. The relevant "environmental" input is febrile/inflammatory stress as a cluster precipitant.
Lifestyle factors: not a driver of disease occurrence; fever management and illness avoidance matter for cluster prevention.
Infectious agents: not causal, but intercurrent infection (via fever/inflammation) is the leading cluster trigger. This is a candidate node for a BBB/neuroinflammation mechanism rather than a pathogen-specific one.

6. Mechanism / Pathophysiology

This is the meaty part, and it's genuinely one of the more elegant puzzles in epilepsy genetics. Think of it like a tissue that only misbehaves when you mix two paint colors — a wall painted all one color (all-mutant hemizygous male) looks fine; a wall with random patches of two colors (mosaic female) develops the crack.

The protein's day job. PCDH19 is a calcium-dependent adhesion molecule. It does homophilic binding (PCDH19-cell to PCDH19-cell) and partners with N-cadherin (CDH2) at adherens junctions to form a strongly adhesive complex. Through this it governs neural progenitor division balance, neuronal migration, axon outgrowth, and synaptogenesis — the scaffolding of a properly wired cortex.

Causal chain (upstream → downstream):

Trigger — PCDH19 LoF variant in a mosaic context. Random X-inactivation in females (or postzygotic mutation in males) yields a salt-and-pepper mixture of PCDH19-positive and PCDH19-negative neurons.
Cellular interference / abnormal cell sorting. The two populations mis-sort and mis-communicate at their boundaries — the mixed population is what's pathogenic, uniform populations are not. Pederick et al. (Neuron 2018, PMID:29429936 — verify) showed abnormal cell sorting segregating wild-type from mutant cells in mosaic mouse cortex, the mechanistic cornerstone of the "why females, not hemizygous males" riddle.
Altered neurogenesis (parallel/contributing arm). Patient-iPSC and cortical-organoid models (PMC8268119; PMC11024992) show accelerated/precocious neurogenesis, a shift toward asymmetric progenitor divisions, premature differentiation, longer neurites, up-regulated neurogenic markers (NCAD, MAP2, TUBB3), mitotic-spindle/centrosome abnormalities (PCDH19 colocalizes with γ-tubulin; ~17% multipolar metaphases vs 4% control), and smaller organoids. Notably, a Xenopus model (PNAS 2024, PMC on pnas.org) argues some phenotypes are mosaicism-independent, so cellular interference isn't the whole story.
Neurosteroid / GABAergic arm. PCDH19 dysfunction down-regulates allopregnanolone synthesis (a potent positive allosteric modulator of GABA_A receptors). Reduced allopregnanolone → decreased GABA_A-mediated inhibition → tilted excitation/inhibition balance. Emerging interneuron data (2025 mouse preprint, biorxiv 688097) show focal reductions in parvalbumin-expressing cortical interneurons and hyperthermic seizure susceptibility — a concrete substrate for both the E/I imbalance and the fever sensitivity.
E/I imbalance → hyperexcitability → seizures. The convergent endpoint: network hyperexcitability and hypersynchrony → clustered focal seizures, fever-facilitated.
Neurodevelopmental output. The same adhesion/migration/neurogenesis disruption yields the ID/ASD/behavioral phenotype in parallel with the epilepsy.

Additional proposed contributors (Trivisano et al., Epilepsy & Behavior 2024, S1525-5050(24)00111-2): asymmetric cell division/heterochrony, altered steroid-gene expression, blood–brain-barrier dysfunction (a candidate mediator of fever-triggered clusters), and reduced GABA_A function.

Cell types / processes for annotation: - Cell types: CL:0000617 GABAergic neuron; CL:0000561 — use CL:0000499 stromal? no — use CL:0011005 GABAergic interneuron / CL:0000598 pyramidal neuron; CL:0000031 neuroblast (neural progenitor); parvalbumin interneuron (CL for cortical interneuron). - Biological processes: GO:0007156 homophilic cell adhesion via plasma-membrane adhesion molecules; GO:0007399 nervous system development; GO:0001764 neuron migration; GO:0022008 neurogenesis; GO:0051301 cell division / GO:0000278 mitotic cell cycle; GO:0006874 cellular calcium ion homeostasis; neurosteroid-relevant GO:0006702 androgen biosynthetic process / allopregnanolone synthesis; GO:0060078 regulation of postsynaptic membrane potential (GABA_A).

This is a place to lean on the project's epilepsy_excitation_inhibition_imbalance module — the "excitation-inhibition imbalance → neuronal hyperexcitability/hypersynchrony → seizure generation" chain (conformance target epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance) fits PCDH19-CE's downstream endpoint cleanly, with the PCDH19-specific upstream (mosaic cellular interference + allopregnanolone/GABA_A) substituted in.

7. Anatomical Structures Affected

Organ / system: central nervous system (UBERON:0000955 brain), specifically cerebral cortex (UBERON:0000956) and limbic/frontal networks (fear/affective seizure semiology implicates temporo-limbic circuitry). Body system: nervous system (UBERON:0001016).
Tissue / cell: cortical neural progenitors (ventricular/subventricular zone), GABAergic interneurons (incl. parvalbumin-expressing), excitatory pyramidal neurons. → CL terms in §6.
Subcellular: adherens junctions / cell–cell junctions (GO:0005912), plasma membrane (GO:0005886), centrosome / mitotic spindle (GO:0005813, GO:0005819), and GABA_A-receptor-bearing postsynaptic membrane (GO:0045211).
Localization / lateralization: brain imaging (MRI) is usually normal/nonspecific; no consistent focal lesion. Seizures are focal but multifocal/bilateral-capable; no fixed lateralization.

8. Temporal Development

Onset: infantile/early-childhood, mean ~10–12 months (range ~2 months to 3–5 years). Onset is typically subacute, heralded by a fever-triggered seizure cluster.
Progression / course: episodic-clustering superimposed on a chronic neurodevelopmental disorder. Clusters recur (often every few weeks to months, illness-linked) then, characteristically, seizures tend to attenuate with age.
Remission: at age ≥11, ~28% seizure-free; mean seizure "offset" age ~17.6 years (range 11–38); ~14% reach 10-year resolution (Kolc 2020). Seizures frequently ease in adolescence — but neuropsychiatric burden persists and adult psychiatric risk rises, so "seizure remission" ≠ "recovery."
Critical windows: the infantile/early-childhood window (active neurogenesis + first fever exposures) is when both epileptogenesis and developmental impact are set — the rationale for early diagnosis and cluster-abortive strategies.

9. Inheritance and Population

Inheritance pattern: X-linked with an unusual sex-limited expression — heterozygous females and mosaic males affected; hemizygous ("transmitting") males spared. This is not standard X-linked recessive or dominant; model it explicitly. The mechanism is cellular interference / mosaic-dependent (§6). → HPO mode-of-inheritance: HP:0001417 X-linked inheritance (with a note on the female-limited, mosaic-dependent expression — this is a genuine curation nuance worth a discussion/knowledge-gap block).
Penetrance: high in females — ~97% of pathogenic-variant-carrying females are affected (~3% asymptomatic carriers).
Expressivity: highly variable (normal cognition + limited seizures → severe DEE), even within families.
Anticipation: not a repeat-expansion disorder; no anticipation.
Germline/somatic mosaicism: central — affected males are somatic mosaics; unaffected transmitting fathers pass the variant to affected daughters; germline/gonadal mosaicism in a parent can produce recurrence.
Founder effects / consanguinity: not relevant (mostly de novo, private variants; not consanguinity-driven).
Carrier frequency: unaffected hemizygous-male "carriers" transmit; population carrier frequency is not meaningfully tabulated given the de-novo-dominated architecture.
Epidemiology: no precise prevalence figure is established; PCDH19-CE is described as "one of the most common monogenic epilepsies" and the second most clinically relevant epilepsy gene after SCN1A. In SCN1A-negative Dravet-like females, PCDH19 variants are found in ~25% (Depienne 2009). For the KB prevalence block, the honest fill is a qualitative prevalence_class: RARE / Orphanet "rare" with measure_type: UNKNOWN and notes citing the "second most common epilepsy gene" framing — a hard cases-per-100,000 number isn't well sourced.
Demographics: overwhelmingly female; no strong ethnic/geographic clustering (private de novo variants worldwide). Age distribution: pediatric onset, lifelong condition.

10. Diagnostics

Genetic testing is the definitive diagnostic.
Gene panels (epilepsy/DEE panels) and WES/WGS are first-line, especially in females with fever-sensitive clustered seizures who are SCN1A-negative (the classic "looks like Dravet but isn't, and is a girl" scenario). → MAXO MAXO:0000004-adjacent; genetic testing action.
Single-gene PCDH19 sequencing + deletion/duplication analysis (MLPA/CMA) captures point variants and CNVs (deletions, the reported triplication).
Mosaicism-aware testing (deep sequencing) is important in males — standard sequencing can miss low-VAF somatic variants. → repeat/mosaic detection considerations.
Chromosomal microarray for large deletions/duplications.
EEG: interictal often normal early; ictal recordings show focal onsets (frontotemporal), sometimes multifocal. No pathognomonic pattern. → electrophysiology (EEG).
MRI: typically normal or nonspecific — helps exclude structural mimics rather than confirm.
Biomarkers: reduced serum/plasma allopregnanolone (allopregnanolone sulfate, Allo-S) is a mechanistic biomarker and was used to stratify patients in the ganaxolone trial — a candidate but not yet a validated clinical diagnostic. → CHEBI: allopregnanolone CHEBI:50169.
Clinical criteria / differential diagnosis: no formal consensus criteria; diagnosis is gene-confirmed pattern recognition. Differentials: Dravet syndrome (SCN1A) — the top mimic; SCN1B, GABRG2, STXBP1, CDKL5 and other DEEs; febrile seizures plus (GEFS+). The female sex + clustered fever-seizures + SCN1A-negative triad is the key clinical flag.
Screening: not on newborn-screening panels; cascade/carrier testing in families (identifying transmitting males and at-risk female relatives) and prenatal/PGT for known familial variants are the relevant screening applications.

11. Outcome / Prognosis

Survival/mortality: generally not life-limiting for most; lifespan is broadly preserved. SUDEP risk exists as with other DEEs but PCDH19-CE is not characterized by high early mortality. (No robust disease-specific mortality rate published — flag as gap.)
Seizure prognosis: frequently improves with age — ~28% seizure-free by ≥11 yr, offset mean ~17.6 yr (§8).
Neurodevelopmental/psychiatric prognosis is the real story: ID (in the ~44% who have it), ASD (~62%), executive dysfunction (~63%) persist, and adult-onset psychiatric illness (including psychotic/schizophrenia-spectrum disorders) is an increasingly recognized late outcome. So the trajectory is often "seizures fade, the neurodevelopmental/psychiatric load stays."
Prognostic factors: earlier onset and higher seizure frequency predict worse cognitive/behavioral outcome (Kolc 2020, robust associations). Genotype–phenotype correlation is otherwise weak.
QoL/morbidity: high family/behavioral burden (§3).

12. Treatment

There's no cure and no single reliably effective drug — the honest framing from the 2025 systematic review title is literally "Tough to treat." Management is cluster-abortive + broad-spectrum ASM + emerging neurosteroid.

Antiseizure medications (broad-spectrum, polytherapy typical):
Clobazam / benzodiazepines — among the more consistently reported effective agents, both for maintenance and acute clusters. → MAXO pharmacotherapy; CHEBI clobazam CHEBI:31413.
Bromide (potassium bromide) — repeatedly noted as notably effective for PCDH19 clusters (an old drug finding a niche). → CHEBI bromide CHEBI:15858.
Corticosteroids / ACTH — used for acute cluster interruption (case series suggest benefit during severe clusters). → MAXO; CHEBI corticosteroid class.
Levetiracetam, valproate, topiramate, stiripentol (single-case benefit), and the ketogenic diet are used with variable/individual response. → MAXO:0000088 dietary intervention (ketogenic diet).
Sodium-channel blockers are less consistently helpful here than in some epilepsies (and unlike in Dravet, are not strictly contraindicated — an important differential-management point).
Neurosteroid / targeted (mechanism-driven):
Ganaxolone — synthetic allopregnanolone analogue, positive allosteric GABA_A modulator, directly targeting the allopregnanolone-deficiency arm. The VIOLET phase-2 RCT (NCT03865732) showed a larger seizure reduction vs placebo (−61.5% vs −24.0%) that did not reach significance (p=0.17) (Epilepsy Res 2023, PMID:36870093). Somnolence was the main AE. → CHEBI ganaxolone; therapeutic_modality: SMALL_MOLECULE; a good candidate for a target_mechanisms link back to the E/I-imbalance / GABA_A node.
Acute cluster / rescue: benzodiazepine rescue protocols; aggressive fever management as prophylaxis against triggers.
Advanced/experimental: no approved gene/RNA therapy; the mosaic mechanism makes gene-replacement conceptually tricky (you can't just flood every cell with wild-type without recreating a "uniform" state). Neurosteroid pharmacology remains the most active targeted avenue.
Supportive/rehabilitative: developmental therapies, ASD/behavioral management, psychiatric surveillance into adulthood, genetic counseling (MAXO:0000079).

Suggested MAXO: MAXO:0000058-type pharmacotherapy / NCIT:C15986 Pharmacotherapy with CHEBI therapeutic_agent per the repo's therapeutic-agent pattern; MAXO:0000088 (ketogenic/dietary); MAXO:0000079 (genetic counseling); MAXO:0000950 (supportive care).

13. Prevention

Primary prevention: none for occurrence (largely de novo). The actionable analog is trigger avoidance — proactive fever/illness management to reduce clusters (a form of tertiary prevention of seizure events).
Secondary prevention: early genetic diagnosis (panel/WES in SCN1A-negative girls with clustered febrile seizures) to enable prompt cluster-management strategies.
Tertiary prevention: aggressive cluster abortion (benzodiazepines/steroids), developmental and psychiatric surveillance to catch adult-onset psychiatric decompensation early.
Genetic prevention: cascade testing, prenatal diagnosis and preimplantation genetic testing for known familial variants; counseling around transmitting-male fathers (all daughters at risk) and parental gonadal mosaicism recurrence risk.
Genetic counseling is central (MAXO:0000079). No immunization or public-health/environmental prevention applies.

14. Other Species / Natural Disease

Taxonomy: Homo sapiens (NCBITaxon:9606) is the disease species. No recognized naturally occurring PCDH19 clustering epilepsy in companion animals or wildlife (OMIA has no established natural-disease entry) — this is essentially a human-defined disorder.
Orthologs: Pcdh19 is evolutionarily conserved across vertebrates — mouse (Pcdh19, NCBI Gene), rat, and zebrafish (pcdh19, a well-studied ortholog with roles in neuronal columnar organization and retinal/neural development). Conservation of the adhesion function is high.
Comparative biology: the conserved PCDH19–N-cadherin adhesion and neurodevelopmental roles make cross-species modeling informative; the mosaic-dependence is the feature that must be engineered (it doesn't arise "naturally" in uniform-genotype animals).
Transmission: not applicable (non-infectious, non-zoonotic).

15. Model Organisms

Mouse (Mus musculus, MGI): Pcdh19 knockout / mosaic models are the workhorses. The landmark finding — abnormal cell sorting segregating wild-type vs mutant cortical cells in mosaic (heterozygous female) mice — recapitulates the human sex-specificity logic (Pederick et al., Neuron 2018, PMID:29429936 — verify). A 2025 mouse model shows hyperthermic (fever) seizure susceptibility and focal loss of parvalbumin interneurons (biorxiv 688097), directly modeling fever sensitivity + E/I substrate. Conditional/mosaic-inducible designs are needed because uniform nulls (like hemizygous males) don't show the phenotype — the model must be mosaic.
Rat: a focal-mosaic Pcdh19 rat reproduces brain developmental abnormalities and behavioral phenotypes (PMC9070467).
Zebrafish (Danio rerio, ZFIN): pcdh19 mutants show neurodevelopmental/columnar-organization defects — good for adhesion/neurogenesis biology.
Xenopus: a Pcdh19 frog model reproduces epilepsy-like and repetitive behaviors and argues for mosaicism-independent contributions (PNAS 2024) — a useful counterweight to a pure cellular-interference view.
Cellular / in vitro: patient-derived iPSCs, 2D neural cultures, cortical/brain organoids (PMC8268119, PMC11024992, PMC8998847) — these captured accelerated neurogenesis, asymmetric-division shift, mitotic-spindle/centrosome defects, altered calcium signaling, and abnormal cell sorting in mixed populations. A Neurogenin-2-induction iPSC model (Alaverdian et al., Epileptic Disord 2023, epd2.20065) is a recent addition. These are the natural home for evidence_source: IN_VITRO; the mouse/rat/zebrafish/Xenopus data are MODEL_ORGANISM.
Model characteristics / limitations: models recapitulate cell-sorting, neurogenesis, fever-susceptibility, and behavior, but no single model reproduces the full human syndrome (seizure semiology + variable ID/ASD + adult psychiatric risk). The human-specific neurodevelopmental context (and the difficulty of matching human XCI mosaic ratios) is a recognized translational gap — a good candidate for a HUMAN_MODEL_MISMATCH discussion block rather than a plain knowledge gap.

Curation notes / suggested KB scaffolding

Identifiers to seed: disease_term → MONDO:0010246; causal gene → hgnc:14270; OMIM *300460 / #300088; ORPHA:101039.
Module conformance: strong fit for epilepsy_excitation_inhibition_imbalance at #Excitation-Inhibition Imbalance, with PCDH19-specific upstream nodes (mosaic cellular interference → abnormal cell sorting → allopregnanolone/GABA_A deficit).
Inheritance block: bind HP:0001417 X-linked inheritance but add a discussions KNOWLEDGE_GAP noting the female-limited, mosaic-dependent, cellular-interference expression that standard X-linked terms don't capture. The germline/gonadal-mosaicism recurrence route is worth an explicit note.
Prevalence: qualitative RARE / measure_type: UNKNOWN, notes = "second most common monogenic epilepsy gene after SCN1A; ~25% of SCN1A-negative Dravet-like females."
Ganaxolone treatment: clinical-trial block citing NCT03865732 + target_mechanisms to the GABA_A/E-I node; therapeutic_agent allopregnanolone-analogue (CHEBI).
Human-model-mismatch discussion: the mosaicism-independent Xenopus findings vs the cell-sorting mouse model make a genuine open question about which mechanism dominates in human disease.

PMIDs to verify before use (leads, per project SOP): 32366910 (Kolc phenotype spectrum — fetched, solid), 36870093 (ganaxolone VIOLET — solid), 19752159 (Depienne de novo — from PubMed link), 34201522 (protocadherin structure review — from source, verify), 29429936 (Pederick cell-sorting — verify digits), 18469813 (Dibbens 2008 EFMR discovery — verify), 19282977 (Depienne 2009 PLoS Genet — verify), 18216183 (Scheffer 2008 Brain EFMR — verify), 30542067 (Kolc 2019 meta-analysis — verify), Tan et al. 2015 allopregnanolone (find exact PMID). Run each through just fetch-reference and confirm the snippet is an exact abstract substring.

Sources: - OMIM #300088 (DEE9) · OMIM *300460 (PCDH19) · Orphanet: PCDH19 - MalaCards: DEE9 - Kolc et al. 2020, standardized phenotype spectrum (PMC7198503) · Transl Psychiatry version - Dissecting PCDH19 in clustering epilepsy — iPSC neurogenesis (PMC8268119) · Cortical organoid cell-sorting model (PMC11024992) · 2D→3D organoid modeling (PMC8998847) - Trivisano et al., pathophysiology & clinical significance, Epilepsy & Behavior 2024 - Ganaxolone VIOLET phase-2 trial (PMID:36870093) · Neurosteroids & PCDH19 (IJMS 2021) - "Tough to treat" systematic review, Seizure 2025 - Mosaicism-independent mechanisms, Xenopus (PNAS 2024) · Focal-mosaic rat model (PMC9070467) · Parvalbumin interneuron mouse preprint 2025 - Depienne et al., de novo/single-generation EFMR (PMID:19752159) · Sporadic IEE resembling Dravet (PMC2633044) · Mutations/deletions in PCDH19 (PMC3033517) - Mosaic males: genotype & VAF (PMC9669318) · PCDH19 triplication mechanism (PMC11506946) · Epilepsiome: PCDH19 primer

One honest caveat before you build the entry: I couldn't get OMIM's and MedLink's pages to open directly (they threw 403s at the fetcher), so the OMIM-derived facts here lean on the MONDO record and the search summaries rather than the primary OMIM text — worth a manual glance when you're pinning down the original-reference PMIDs.

PCDH19 Clustering Epilepsy

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Source YAML

References & Deep Research

Deep Research

PCDH19 Clustering Epilepsy — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation notes / suggested KB scaffolding